Trial Profile
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Opicapone (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Neurocrine Biosciences
- 27 Apr 2023 Results of pooled post-hoc analysis included data from 2 open-label Phase 1 studies (NCT01533077and NCT03496870 presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 23 Jan 2023 Results assessing pharmacokinetics and pharmacodynamics of once-daily opicapone 50 mg adjunctive to CD/LD in patients with stable parkinson disease published in the Clinical Neuropharmacology
- 18 Sep 2022 Results of post-hoc analysis included data from 2 open-label Phase 1 studies (NCT01533077and NCT03496870), presented at the 26th International Congress of Parkinson's Disease and Movement Disorders.